Literature DB >> 10879934

Current options in the management of apnea of prematurity.

J Bhatia1.   

Abstract

Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants. Apnea of prematurity appears to be due to immaturity of the infant's neurologic and respiratory systems. Apnea of prematurity is a diagnosis of exclusion that can be made only when other possible infectious, cardiologic, physiologic, and metabolic causes of apnea have been ruled out. The fundamental principles for managing apnea of prematurity include monitoring the infant closely while instituting supportive care measures such as tactile stimulation, continuous positive airway pressure, or mechanical ventilation. When necessary, pharmacologic therapy may be used to stimulate breathing. The first-line agents of choice for the management of AOP are the methylxanthines. And, for second-line therapy, a switch to a different class of agent, such as the respiratory stimulant doxapram, is an option. Of the methylxanthines, theophylline is the most extensively used. However, a review of the literature suggests that caffeine citrate may be the agent of choice for AOP. Comparative clinical studies have demonstrated that caffeine is at least as effective as theophylline, has a longer half-life, is associated with fewer adverse events, and, in addition, has a greater ease of administration. Caffeine stimulates the respiratory and central nervous systems more effectively and penetrates into the cerebrospinal fluid more readily than theophylline. In addition, because of stable plasma levels, caffeine has a wide therapeutic margin and few side effects. In contrast, theophylline plasma levels may fluctuate widely, which necessitates frequent monitoring and has a higher incidence of adverse events than caffeine. Before the FDA approval of caffeine citrate (Cafcit) for administration either intravenously and/or orally, caffeine preparations were "homemade." A few studies suggest that use of pharmacotherapy to treat AOP is not generally associated with long-term sequelae, although more data are needed before this can be definitively concluded.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10879934     DOI: 10.1177/000992280003900602

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  14 in total

Review 1.  Apnea in the newborn.

Authors:  R Aggarwal; A Singhal; A K Deorari; V K Paul
Journal:  Indian J Pediatr       Date:  2001-10       Impact factor: 1.967

Review 2.  Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity.

Authors:  Katherine Schoen; Tian Yu; Chris Stockmann; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

3.  Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants.

Authors:  Nicole R Dobson; Ravi M Patel; P Brian Smith; Devon R Kuehn; Jennifer Clark; Shilpa Vyas-Read; Amy Herring; Matthew M Laughon; David Carlton; Carl E Hunt
Journal:  J Pediatr       Date:  2014-01-23       Impact factor: 4.406

4.  Identification of apnea during respiratory monitoring using support vector machine classifier: a pilot study.

Authors:  Paruthi Pradhapan; Muthukaruppan Swaminathan; Hari Krishna Salila Vijayalal Mohan; N Sriraam
Journal:  J Clin Monit Comput       Date:  2012-11-21       Impact factor: 2.502

Review 5.  Apnea in the newborn.

Authors:  Satish Mishra; Ramesh Agarwal; M Jeevasankar; Rajiv Aggarwal; Ashok K Deorari; Vinod K Paul
Journal:  Indian J Pediatr       Date:  2008-01       Impact factor: 1.967

Review 6.  Caffeine citrate: a review of its use in apnoea of prematurity.

Authors:  A M Comer; C M Perry; D P Figgitt
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.930

7.  Low dose aminophylline effectively decreases the risk of post-operative apnea in premature infants.

Authors:  Seyed Amir Mohajerani; Fatemeh Roodneshin
Journal:  Tanaffos       Date:  2014

8.  Generation of eupnea and sighs by a spatiochemically organized inspiratory network.

Authors:  Araya Ruangkittisakul; Stephan W Schwarzacher; Lucia Secchia; Yonglie Ma; Nicoleta Bobocea; Betty Y Poon; Gregory D Funk; Klaus Ballanyi
Journal:  J Neurosci       Date:  2008-03-05       Impact factor: 6.709

9.  Predictive Factors for Efficacy and Safety of Prophylactic Theophylline for Extubation in Infants with Apnea of Prematurity.

Authors:  Tomoko Kondo; Yuki Kondo; Yuji Orita; Fumi Mitarai; Yoichi Ishitsuka; Mitsuru Irikura; Yoshihiro Shimodozono; Tsutomu Douchi; Yasuo Takeda; Tetsumi Irie
Journal:  PLoS One       Date:  2016-07-07       Impact factor: 3.240

10.  The efficacy and safety of two different doses of caffeine in respiratory function of preterm infants.

Authors:  Fatemeh Faramarzi; Mohammadreza Shiran; Mohammadreza Rafati; Roya Farhadi; Ebrahim Salehifar; Maryam Nakhshab
Journal:  Caspian J Intern Med       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.